Antiserum against PreS2 peptide was raised with a synthetic polypeptide from the rabbits.The anti-preS2 antibody and polymerized human serum albumin were used as reagents in aradioimmunoassay to detect preS2 and polym...Antiserum against PreS2 peptide was raised with a synthetic polypeptide from the rabbits.The anti-preS2 antibody and polymerized human serum albumin were used as reagents in aradioimmunoassay to detect preS2 and polymerized human serum albumin bindingactivity respectively. Both were absent in patients with hepatitis A or HBsAg negative chronic liver di-seases. In biopsy - proven patients with chronic active hepatitis (CAH)B, prevalences of bothmarkers were significantly higher at exacerbation that at remission stage of the disease, and so werein CAH than in chronic asymptomatic HBV carrier (AsC) with normal histology. Besides, the pre-valences were significantly higher in HBeAg positive group than in anti-HBe positive group.However, the polymerized human serum albumin binding activity and the preS2 were undoubtedlynot the same, as the prevalence of the latter was only 56.7% of the former.展开更多
目的了解乙型肝炎病毒(hepatitis B virus,HBV)相关慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)合并院内真菌感染患者抗感染药物的应用情况,为此类患者临床合理应用抗感染药物提供依据。方法对解放军第三0二医院1985年1月至2...目的了解乙型肝炎病毒(hepatitis B virus,HBV)相关慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)合并院内真菌感染患者抗感染药物的应用情况,为此类患者临床合理应用抗感染药物提供依据。方法对解放军第三0二医院1985年1月至2006年6月发生院内真菌感染的353例患者,HBV相关ACLF的临床资料进行分析。结果有257例(72.80%)患者在真菌感染前发生了细菌感染,发生院内真菌感染前使用过抗生素者319例(90.37%),以三代头孢类、喹诺酮类多见。患者发生院内真菌感染时,血清丙氨酸转氨酶(ALT)、总胆红素(TBIL)水平与抗生素使用时间、种类均呈正相关(P<0.05),抗生素使用时间与距院内真菌感染时间呈正相关(P<0.01)。不符合抗生素联合用药标准比例为18.81%。激素使用时间与距院内真菌感染时间呈正相关(P<0.01)。共发生院内真菌感染510例次,发生院内真菌感染后323例患者(91.50%)使用抗真菌药物治疗,以氟康唑、大蒜素多见,死亡率为37.59%。患者抗真菌感染疗效与最终的转归呈正相关(P<0.01),Spearman等级相关系数=0.6455。结论 HBV相关ACLF患者由于存在机体抵抗力差、并发症、细菌感染、不合理使用抗生素、长期使用激素等原因,导致容易合并院内真菌感染,发生院内真菌感染后患者预后差,抗真菌感染疗效与其总体预后情况密切相关,临床需要重视此类患者抗感染药物的应用问题。展开更多
慢性乙型肝炎病毒(Hepatitis B Virus,HBV)感染可诱发肝硬化与肝癌,是危害人类健康的重大疾病。基于对HBV感染持续不愈主要是机体免疫功能缺陷所致的认识,提出用"合成免疫"策略重建抗HBV免疫功能,消除感染以预防致命病变的发...慢性乙型肝炎病毒(Hepatitis B Virus,HBV)感染可诱发肝硬化与肝癌,是危害人类健康的重大疾病。基于对HBV感染持续不愈主要是机体免疫功能缺陷所致的认识,提出用"合成免疫"策略重建抗HBV免疫功能,消除感染以预防致命病变的发生。用优化的基因治疗载体微环DNA,在体内表达一套工程抗体,模拟急性HBV感染康复时机体的免疫反应,由单克隆抗体中和病毒,双靶向抗体将非特异的T淋巴细胞转化为抗HBV的T淋巴细胞,杀死HBV感染的肝细胞,两者协同达到根治慢性HBV感染的目的。微环DNA安全、经济,可建立一个安全、高效、可负担的抗HBV免疫体系,有效消除HBV的危害。展开更多
核苷(酸)类似物(nucleos(t)ide analogues,NAs)耐药乙型肝炎病毒(hepatitis B virus,HBV)感染是由长期使用药物后HBV逆转录酶区的基因突变导致。耐药性的出现可导致治疗失败,也是疾病进展的重要原因之一。阐明HBV耐药机制对于药物选择...核苷(酸)类似物(nucleos(t)ide analogues,NAs)耐药乙型肝炎病毒(hepatitis B virus,HBV)感染是由长期使用药物后HBV逆转录酶区的基因突变导致。耐药性的出现可导致治疗失败,也是疾病进展的重要原因之一。阐明HBV耐药机制对于药物选择及预后治疗具有重要帮助;梳理HBV耐药的突变位点现状将为进一步探讨耐药HBV的相关风险信号及临床精准防控提供依据。本文就NAs耐药乙肝的分子机制与突变位点研究进行简要综述,旨在为耐药乙肝的治疗提供参考。展开更多
文摘Antiserum against PreS2 peptide was raised with a synthetic polypeptide from the rabbits.The anti-preS2 antibody and polymerized human serum albumin were used as reagents in aradioimmunoassay to detect preS2 and polymerized human serum albumin bindingactivity respectively. Both were absent in patients with hepatitis A or HBsAg negative chronic liver di-seases. In biopsy - proven patients with chronic active hepatitis (CAH)B, prevalences of bothmarkers were significantly higher at exacerbation that at remission stage of the disease, and so werein CAH than in chronic asymptomatic HBV carrier (AsC) with normal histology. Besides, the pre-valences were significantly higher in HBeAg positive group than in anti-HBe positive group.However, the polymerized human serum albumin binding activity and the preS2 were undoubtedlynot the same, as the prevalence of the latter was only 56.7% of the former.
文摘慢性乙型肝炎病毒(Hepatitis B Virus,HBV)感染可诱发肝硬化与肝癌,是危害人类健康的重大疾病。基于对HBV感染持续不愈主要是机体免疫功能缺陷所致的认识,提出用"合成免疫"策略重建抗HBV免疫功能,消除感染以预防致命病变的发生。用优化的基因治疗载体微环DNA,在体内表达一套工程抗体,模拟急性HBV感染康复时机体的免疫反应,由单克隆抗体中和病毒,双靶向抗体将非特异的T淋巴细胞转化为抗HBV的T淋巴细胞,杀死HBV感染的肝细胞,两者协同达到根治慢性HBV感染的目的。微环DNA安全、经济,可建立一个安全、高效、可负担的抗HBV免疫体系,有效消除HBV的危害。
文摘核苷(酸)类似物(nucleos(t)ide analogues,NAs)耐药乙型肝炎病毒(hepatitis B virus,HBV)感染是由长期使用药物后HBV逆转录酶区的基因突变导致。耐药性的出现可导致治疗失败,也是疾病进展的重要原因之一。阐明HBV耐药机制对于药物选择及预后治疗具有重要帮助;梳理HBV耐药的突变位点现状将为进一步探讨耐药HBV的相关风险信号及临床精准防控提供依据。本文就NAs耐药乙肝的分子机制与突变位点研究进行简要综述,旨在为耐药乙肝的治疗提供参考。
